
Terry A. Wallace
Examiner (ID: 8615, Phone: (571)272-2630 , Office: P/2916 )
| Most Active Art Unit | 2916 |
| Art Unit(s) | 2912, 2900, 2902, 2916 |
| Total Applications | 11456 |
| Issued Applications | 11361 |
| Pending Applications | 3 |
| Abandoned Applications | 90 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20555418
[patent_doc_number] => 20260055198
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2026-02-26
[patent_title] => METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST
[patent_app_type] => utility
[patent_app_number] => 19/385591
[patent_app_country] => US
[patent_app_date] => 2025-11-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20313
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19385591
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/385591 | METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST | Nov 10, 2025 | Pending |
Array
(
[id] => 19910267
[patent_doc_number] => 12286463
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2025-04-29
[patent_title] => Interleukin 18 (IL-18) variants and fusion proteins comprising same
[patent_app_type] => utility
[patent_app_number] => 18/948648
[patent_app_country] => US
[patent_app_date] => 2024-11-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 14
[patent_no_of_words] => 8091
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18948648
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/948648 | Interleukin 18 (IL-18) variants and fusion proteins comprising same | Nov 14, 2024 | Issued |
Array
(
[id] => 19707878
[patent_doc_number] => 20250018020
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-16
[patent_title] => IL-15-BASED FUSIONS TO IL-12 AND IL-18
[patent_app_type] => utility
[patent_app_number] => 18/896286
[patent_app_country] => US
[patent_app_date] => 2024-09-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29907
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18896286
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/896286 | IL-15-based fusions to IL-12 and IL-18 | Sep 24, 2024 | Issued |
Array
(
[id] => 19601137
[patent_doc_number] => 20240392017
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-28
[patent_title] => HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATION
[patent_app_type] => utility
[patent_app_number] => 18/792080
[patent_app_country] => US
[patent_app_date] => 2024-08-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7575
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18792080
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/792080 | HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATION | Jul 31, 2024 | Abandoned |
Array
(
[id] => 19571927
[patent_doc_number] => 20240376219
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-14
[patent_title] => HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATION
[patent_app_type] => utility
[patent_app_number] => 18/780956
[patent_app_country] => US
[patent_app_date] => 2024-07-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7577
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18780956
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/780956 | HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATION | Jul 22, 2024 | Abandoned |
Array
(
[id] => 19550939
[patent_doc_number] => 12134635
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-11-05
[patent_title] => Interleukin 18 (IL-18) variants and fusion proteins comprising same
[patent_app_type] => utility
[patent_app_number] => 18/740390
[patent_app_country] => US
[patent_app_date] => 2024-06-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 14
[patent_no_of_words] => 13282
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 163
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18740390
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/740390 | Interleukin 18 (IL-18) variants and fusion proteins comprising same | Jun 10, 2024 | Issued |
Array
(
[id] => 19701511
[patent_doc_number] => 12195520
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-14
[patent_title] => Advanced avatar dendritic cells
[patent_app_type] => utility
[patent_app_number] => 18/679187
[patent_app_country] => US
[patent_app_date] => 2024-05-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10016
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 175
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18679187
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/679187 | Advanced avatar dendritic cells | May 29, 2024 | Issued |
Array
(
[id] => 19464200
[patent_doc_number] => 20240317869
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-26
[patent_title] => HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATION
[patent_app_type] => utility
[patent_app_number] => 18/656957
[patent_app_country] => US
[patent_app_date] => 2024-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7572
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18656957
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/656957 | HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATION | May 6, 2024 | Abandoned |
Array
(
[id] => 19418507
[patent_doc_number] => 20240294630
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-05
[patent_title] => BIOPHARMACEUTICAL COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 18/650566
[patent_app_country] => US
[patent_app_date] => 2024-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40961
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18650566
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/650566 | Biopharmaceutical compositions | Apr 29, 2024 | Issued |
Array
(
[id] => 19418505
[patent_doc_number] => 20240294628
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-05
[patent_title] => BIOPHARMACEUTICAL COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 18/650526
[patent_app_country] => US
[patent_app_date] => 2024-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40973
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18650526
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/650526 | Biopharmaceutical compositions | Apr 29, 2024 | Issued |
Array
(
[id] => 19418506
[patent_doc_number] => 20240294629
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-05
[patent_title] => BIOPHARMACEUTICAL COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 18/650552
[patent_app_country] => US
[patent_app_date] => 2024-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40973
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18650552
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/650552 | Biopharmaceutical compositions | Apr 29, 2024 | Issued |
Array
(
[id] => 19332611
[patent_doc_number] => 20240247041
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-25
[patent_title] => Il-2 Mutant And Application Thereof
[patent_app_type] => utility
[patent_app_number] => 18/626591
[patent_app_country] => US
[patent_app_date] => 2024-04-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16549
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18626591
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/626591 | IL-2 mutant and application thereof | Apr 3, 2024 | Issued |
Array
(
[id] => 19332610
[patent_doc_number] => 20240247040
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-25
[patent_title] => INTERLEUKIN-2 AGENTS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/616055
[patent_app_country] => US
[patent_app_date] => 2024-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 90781
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18616055
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/616055 | Interleukin-2 agents and uses thereof | Mar 24, 2024 | Issued |
Array
(
[id] => 19343646
[patent_doc_number] => 20240252609
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-01
[patent_title] => IL-15-BASED FUSIONS TO IL-12 AND IL-18
[patent_app_type] => utility
[patent_app_number] => 18/611464
[patent_app_country] => US
[patent_app_date] => 2024-03-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29908
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18611464
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/611464 | IL-15-BASED FUSIONS TO IL-12 AND IL-18 | Mar 19, 2024 | Abandoned |
Array
(
[id] => 19379379
[patent_doc_number] => 20240269249
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-15
[patent_title] => METHODS OF TREATING ATOPIC DERMATITIS
[patent_app_type] => utility
[patent_app_number] => 18/443459
[patent_app_country] => US
[patent_app_date] => 2024-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40091
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18443459
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/443459 | METHODS OF TREATING ATOPIC DERMATITIS | Feb 15, 2024 | Pending |
Array
(
[id] => 19543175
[patent_doc_number] => 20240360211
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-31
[patent_title] => TREATMENT OF FIBROSIS
[patent_app_type] => utility
[patent_app_number] => 18/436088
[patent_app_country] => US
[patent_app_date] => 2024-02-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33232
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18436088
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/436088 | TREATMENT OF FIBROSIS | Feb 7, 2024 | Pending |
Array
(
[id] => 19642958
[patent_doc_number] => 20240417478
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-19
[patent_title] => ANTIBODIES AGAINST IL-7R ALPHA SUBUNIT AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/423762
[patent_app_country] => US
[patent_app_date] => 2024-01-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48791
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18423762
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/423762 | ANTIBODIES AGAINST IL-7R ALPHA SUBUNIT AND USES THEREOF | Jan 25, 2024 | Pending |
Array
(
[id] => 19403640
[patent_doc_number] => 20240287151
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-29
[patent_title] => IL-15 Conjugates and Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 18/415445
[patent_app_country] => US
[patent_app_date] => 2024-01-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40302
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18415445
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/415445 | IL-15 Conjugates and Uses Thereof | Jan 16, 2024 | Pending |
Array
(
[id] => 19156158
[patent_doc_number] => 20240148865
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-09
[patent_title] => Induction of IL-12 using immunotherapy
[patent_app_type] => utility
[patent_app_number] => 18/415111
[patent_app_country] => US
[patent_app_date] => 2024-01-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5364
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18415111
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/415111 | Induction of IL-12 using immunotherapy | Jan 16, 2024 | Pending |
Array
(
[id] => 19233767
[patent_doc_number] => 20240190959
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => Antigen Binding Proteins that Bind PD-L1
[patent_app_type] => utility
[patent_app_number] => 18/412102
[patent_app_country] => US
[patent_app_date] => 2024-01-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19800
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18412102
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/412102 | Antigen Binding Proteins that Bind PD-L1 | Jan 11, 2024 | Pending |